[
  {
    "ts": null,
    "headline": "Novo Nordisk Shares Plunge After New Obesity Shot Disappoints",
    "summary": "Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of becoming the company’s next blockbuster weight loss drug.",
    "url": "https://finnhub.io/api/news?id=9ee3a9cdcf66fd04e663d7ee60b6f67cbc9e6ae9267b93420a2dc44abe95cd38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734724080,
      "headline": "Novo Nordisk Shares Plunge After New Obesity Shot Disappoints",
      "id": 132080045,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of becoming the company’s next blockbuster weight loss drug.",
      "url": "https://finnhub.io/api/news?id=9ee3a9cdcf66fd04e663d7ee60b6f67cbc9e6ae9267b93420a2dc44abe95cd38"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer",
    "summary": "NEW YORK, December 20, 2024--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.i The indication was approved based on a statistically significant and clinically meaningful improve",
    "url": "https://finnhub.io/api/news?id=6458c74f2f9d48d902e4399ce84946440e491bcc7f77fc7167de293f93f953c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734721380,
      "headline": "U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer",
      "id": 132078969,
      "image": "https://media.zenfs.com/en/business-wire.com/4d4f516256d29fad43575fb501821bfd",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, December 20, 2024--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.i The indication was approved based on a statistically significant and clinically meaningful improve",
      "url": "https://finnhub.io/api/news?id=6458c74f2f9d48d902e4399ce84946440e491bcc7f77fc7167de293f93f953c3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Gains FDA Approval for Colorectal-Cancer Treatment",
    "summary": "By Katherine Hamilton Pfizer said Friday that the Food and Drug Administration approved its treatment for patients with metastatic colorectal cancer. The FDA approved braftovi in combination...",
    "url": "https://finnhub.io/api/news?id=cf7334814392ae0f66379c84bbd709df9acb496bd6aee535e02fe92ca85bce25",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734707654,
      "headline": "Pfizer Gains FDA Approval for Colorectal-Cancer Treatment",
      "id": 132078605,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Katherine Hamilton Pfizer said Friday that the Food and Drug Administration approved its treatment for patients with metastatic colorectal cancer. The FDA approved braftovi in combination...",
      "url": "https://finnhub.io/api/news?id=cf7334814392ae0f66379c84bbd709df9acb496bd6aee535e02fe92ca85bce25"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals",
    "summary": "PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.",
    "url": "https://finnhub.io/api/news?id=9a7f693ca872f0729cbe2b9b4392fe525775d2044fa9cba03809fe27fe1bac3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734697620,
      "headline": "Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals",
      "id": 132073302,
      "image": "https://media.zenfs.com/en/zacks.com/afe95824683969079aeba27c8210bd37",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.",
      "url": "https://finnhub.io/api/news?id=9a7f693ca872f0729cbe2b9b4392fe525775d2044fa9cba03809fe27fe1bac3b"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now?",
    "summary": "We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other cheap NYSE stocks to invest in now. The stock market appears poised for another year of impressive returns, likely extending into 2025. However, […]",
    "url": "https://finnhub.io/api/news?id=fd0eb9f6dca890bccfc998025357e78445ac99332819de42c16999aa6b3cc268",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734697161,
      "headline": "Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now?",
      "id": 132078972,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other cheap NYSE stocks to invest in now. The stock market appears poised for another year of impressive returns, likely extending into 2025. However, […]",
      "url": "https://finnhub.io/api/news?id=fd0eb9f6dca890bccfc998025357e78445ac99332819de42c16999aa6b3cc268"
    }
  },
  {
    "ts": null,
    "headline": "Impax Global Social Leaders Fund Q3 2024 Commentary",
    "summary": "The Impax Global Social Leaders Fund outperformed its benchmark in Q3 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=e651f71d040238d0ebf948fb056358b6525f4992bfc1c98079d40b51988571e5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734674100,
      "headline": "Impax Global Social Leaders Fund Q3 2024 Commentary",
      "id": 132070571,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1460957313/image_1460957313.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The Impax Global Social Leaders Fund outperformed its benchmark in Q3 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=e651f71d040238d0ebf948fb056358b6525f4992bfc1c98079d40b51988571e5"
    }
  }
]